Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 2

2(33.3%)

Phase 3

1(16.7%)

6Total

Phase 1(3)

Phase 2(2)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT07072143Recruiting

An International Study on Pediatric Patients With Rare Tumors.

Role: collaborator

NCT02258815Phase 2Completed

CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma

Role: lead

NCT03559413Phase 1Completed

Patient-individualized Peptide Vaccination Based on Tumor-specific Mutations in Children and Young Adults With Primary/Relapsed ALL

Role: lead

NCT04714502Unknown

Asphyxia Associated Metabolite Biomarker Investigation 2

Role: collaborator

NCT03354208Completed

Asphyxia Associated Metabolite Biomarker Investigation (AAMBI)

Role: collaborator

NCT00743496Phase 1Completed

A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma, Osteosarcoma, Ewing Sarcoma and Melanoma

Role: collaborator

NCT01035190Phase 3Completed

Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Role: lead

NCT01919866Phase 1Unknown

Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells

Role: lead

NCT01309178Phase 2Unknown

Anti-inflammatory Pulmonal Therapy of Cystic Fibrosis (CF) Patients With Amitriptyline and Placebo

Role: lead

NCT01040156Completed

Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation

Role: lead

All 10 trials loaded